Colorectal Cancer

Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer

Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer

By

CORRECT and CONCUR trials demonstrated an improvement in OS for patients receiving regorafenib compared with placebo.

Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy

Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy

By

Researchers sought to determine if autophagy-related proteins are associated with survival among patients with CRC.

Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic Sites

Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic Sites

By

In patients with colorectal cancer, rectal tumors and lung metastasis appeared to be linked to an elevated risk for brain cancer.

Cetuximab/Irinotecan Rechallenge Active in Resistant Metastatic Colorectal Cancer

Cetuximab/Irinotecan Rechallenge Active in Resistant Metastatic Colorectal Cancer

By

The CRICKET trial is evaluating the third-line retreatment of patients with mCRC with cetixumab plus irinotecan.

Increasing the Mutant Allele Fraction Cutoff in NGS Improved Mutation Detection in mCRC

Increasing the Mutant Allele Fraction Cutoff in NGS Improved Mutation Detection in mCRC

By

Increasing the sensitivity cutoff from 5% to 1% in next-generation sequencing allowed for the identification of 28% more RAS/BRAF mutations.

Liquid Biopsy Test Accurately Detects <i>RAS</i> Mutations in Metastatic Colorectal Cancer

Liquid Biopsy Test Accurately Detects RAS Mutations in Metastatic Colorectal Cancer

By

The OncoBEAM RAS kit for circulating tumor DNA (ctDNA) analysis of patients with metastatic colorectal cancer (mCRC) demonstrated high positive and negative agreement of RAS mutations detected by tumor tissue analysis.

Patients with advanced adenomas are at increased risk of developing colorectal cancer

In this randomized screening trial, patients with advanced adenomas detected by flex sigmoidoscopy (FSG) were at significantly increased risk of CRC compared to those with no adenomas.

BEACON CRC Safety Lead-in Study suggests safety and efficacy of triplet combination therapy for treatment of metastatic colorectal cancer

Preliminary analysis of the Safety Lead-in Study for the BEACON CRC reveals that the triplet combination is generally well tolerated and has promising clinical activity with an overall response rate of 41%.

iPad app that allows patients to order tests doubles colon cancer screening rates in study

The authors of this study at Wake Forest School of Medicine aimed to evaluate whether utilizing an iPad app as a digital health intervention could result in higher screening rates for CRC.

Colonoscopy significantly reduces mortality from colorectal cancer in Veterans Affairs study

Colorectal cancer (CRC) screening serves as a critical element of CRC prevention and management. To date, colonoscopy remains the gold standard with respect to CRC screening in the United States.

Obstructing Colorectal Cancer: Presentation and Stenting — In the Clinic

Obstructing Colorectal Cancer: Presentation and Stenting — In the Clinic

By

Colonic stenting can be used as a temporizing measure to help bridge the patient to surgery for optimal timing.

Modified XELIRI Yields Similar Outcomes to FOLFIRI in Metastatic CRC

Modified XELIRI Yields Similar Outcomes to FOLFIRI in Metastatic CRC

By

The purpose of this trial was to determine the efficacy and safety of mXELIRI as a second-line therapy for CRC in an Asian population.

High Nut Intake Improves Survival Among Patients With Colon Cancer

High Nut Intake Improves Survival Among Patients With Colon Cancer

By

Nut intake is associated with a reduced risk of type 2 diabetes and insulin resistance.

mFOLFOXIRI Plus Cetuximab May Improve Resection Rate in Metastatic Colorectal Cancer

mFOLFOXIRI Plus Cetuximab May Improve Resection Rate in Metastatic Colorectal Cancer

By

Researchers randomly assigned 143 patients to receive cetuximab plus mFOLFOXIRI followed by cetuximab or bevacizumab maintenance.

Novel pSTAT3 Inhibitor Fails To Prolong OS in Advanced Colorectal Cancer

Novel pSTAT3 Inhibitor Fails To Prolong OS in Advanced Colorectal Cancer

By

Preclinical studies demonstrated that napabucasin — a first-in-class cancer stemness inhibitor that blocks STAT3 — may prevent self-renewal and induce cancer stem cell death.

CTC Screening May Be Effective Method for Preventing Colorectal Cancer

CTC Screening May Be Effective Method for Preventing Colorectal Cancer

By

Current screening methods have a low sensitivity for precancerous lesions and are inconvenient, leading to high rates of noncompliance.

Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC

Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC

By

Researchers treated 74 patients with dMMR/MSI-H mCRC with nivolumab 3 mg/kg every 2 weeks.

Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC

Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC

By

MEK inhibition with cobimetinib may improve the response rate with checkpoint inhibition.

Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors

Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors

By

Survivors assigned to an experimental arm showed an improvement in the FACT-C functional well-being sub-scale from baseline to 12 weeks.

Radiotherapy Dose to Lung Affects Overall Survival Among Patients With Esophageal Cancer

Radiotherapy Dose to Lung Affects Overall Survival Among Patients With Esophageal Cancer

By

Researchers evaluated the outcomes of 453 patients with stage I to III esophageal cancer who received definitive or preoperative chemoradiation.

Aromatase Inhibitors Not Associated With Increased Risk of Colorectal Cancer

Aromatase Inhibitors Not Associated With Increased Risk of Colorectal Cancer

By

After median follow-up of 2.4 and 2.9 years for women who initiated AIs and tamoxifen, respectively, no increased risk of colorectal cancer was observed among women treated with AIs.

Microbiota and Cancer

Microbiota and Cancer

By

Evidence suggests that microbiota dysbiosis occurs among patients with cancer, particularly those with cancers of the digestive tract.

Colorectal Cancer Screening: Utility of Septin-9 Assays

Colorectal Cancer Screening: Utility of Septin-9 Assays

By

While colonoscopy is considered the gold standard screening method for CRC, it can be burdensome to patients; blood tests, while less burdensome, are not necessarily as sensitive.

Proinflammatory Diet and Colorectal Cancer

Proinflammatory Diet and Colorectal Cancer

By

Epidemiologic evidence suggests that a proinflammatory diet, as measured by the dietary inflammatory index, can increase the risk of developing CRC, particularly proximal colon cancer.

Dietary Fiber Reduces Risk of Death Post-colorectal Cancer Diagnosis

Dietary Fiber Reduces Risk of Death Post-colorectal Cancer Diagnosis

By

For this prospective study, researchers evaluated dietary and mortality data from 1575 health care professionals with stage I to III CRC.

Phase 1 Study of Cobimetinib With Bevacizumab and Atezolizumab for Colorectal Cancer

Phase 1 Study of Cobimetinib With Bevacizumab and Atezolizumab for Colorectal Cancer

By

Researchers are evaluating the safety, tolerability, and pharmacokinetics of cobimetinib, an MEK inhibitor, in combination with atezolizumab and bevacizumab among patients with metastatic colorectal cancer.

Phase 1 Trial of Guadecitabine With Vaccine and Cyclophosphamide for Metastatic Colorectal Cancer

Phase 1 Trial of Guadecitabine With Vaccine and Cyclophosphamide for Metastatic Colorectal Cancer

By

Researchers are evaluating whether guadecitabine (SGI-110), a DNA methyltransferase inhibitor, is safe and effective in combination with cyclophosphamide and GVAX among patients with colorectal cancer.

Lifestyle Factors Associated With Colorectal Cancer Survival

Lifestyle Factors Associated With Colorectal Cancer Survival

By

For this follow-up analysis, several lifestyle factors including smoking status, exercise, and alcohol intake were reviewed to determine any relationship with CRC-specific survival.

FDA Approves Bevacizumab-awwb as First Biosimilar for Anticancer Therapy

FDA Approves Bevacizumab-awwb as First Biosimilar for Anticancer Therapy

By

Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.

Labetuzumab May Provide Benefit in R/R Metastatic Colorectal Cancer

Labetuzumab May Provide Benefit in R/R Metastatic Colorectal Cancer

By

Eligible patients had received a median of 5 prior treatment regimens, 1 of which must have included irinotecan.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs